A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered.
Solid Tumor, Adult, Solid Tumor Cancer
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered.
Study of DF6215 in Patients with Advanced Solid Tumors
-
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States, 90025
University of California Irvine Medical Center, Orange, California, United States, 92868
University of California San Diego Moores Cancer Center, San Diego, California, United States, 92093
Sarcoma Oncology Center, Santa Monica, California, United States, 90403
Tampa General Hospital, Tampa, Florida, United States, 33606
Moffitt Cancer Center, Tampa, Florida, United States, 33612
NYU Langone Health, New York, New York, United States, 10016
Lifespan - Rhode Island Hospital, Providence, Rhode Island, United States, 02903
SCRI Oncology Partners, Nashville, Tennessee, United States, 37203
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Dragonfly Therapeutics,
2027-12